Research & Development
IBSA Pharma repurchases Flector marketing and distribution rights from Pfizer
13 January 2021 -

IBSA Pharma Inc, a company involved in topical treatment of acute pain and the treatment of hypothyroidism, has repurchased marketing and distribution rights for Flector (diclofenac epolamine) topical system 1.3% from United States-based Pfizer, it was reported on Tuesday.

With the reacquisition, IBSA is providing two prescription topical drugs, Flector and Licart, intended to treat acute pain due to minor strains, sprains, and contusions. IBSA says that both the products are produced under its strict Quality System control.

The marketing rights for Flector have reverted to IBSA effective January 2021. The company has taken a decision to reduce the price of Flector and offer significant patient savings programs. Licart is the first and only once-a-day topical nonsteroidal anti-inflammatory drug therapy approved by the FDA.

Login
Username:

Password:


Related Headlines